Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:GYRE

Gyre Therapeutics Q2 2024 Earnings Report

Gyre Therapeutics logo
$7.47 0.00 (0.00%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$7.32 -0.15 (-1.94%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Gyre Therapeutics EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Gyre Therapeutics Revenue Results

Actual Revenue
$25.23 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gyre Therapeutics Announcement Details

Quarter
Q2 2024
Date
8/13/2024
Time
N/A
Conference Call Date
Monday, August 12, 2024
Conference Call Time
6:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Gyre Therapeutics' Q2 2024 Press ReleasePress Release
(8-K)
Gyre Therapeutics' Q2 2024 Quarterly ReportQuarterly Report
(10-Q)

Gyre Therapeutics Earnings Headlines

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3289709/0/en/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update.html
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3286729/0/en/gyre-therapeutics-completes-acquisition-of-cullgen-to-create-u-s-and-china-based-fully-integrated-biopharmaceutical-company.html
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.tc pixel
 |  Banyan Hill Publishing (Ad)
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
March 17, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/gyre-therapeutics-announces-china-s-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment-1035936419
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
March 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/17/3257004/0/en/gyre-therapeutics-announces-china-s-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment.html
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE)
March 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GYRE/pressreleases/752194/analysts-offer-insights-on-healthcare-companies-optimizerx-oprx-and-gyre-therapeutics-gyre/
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE) is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas. By leveraging its platform to validate novel targets and generate lead candidates, the company aims to address unmet medical needs where dysregulated lipid environments drive disease progression.

Headquartered in South San Francisco, California, Gyre Therapeutics was founded in 2021 and completed its initial public offering on the Nasdaq Global Market under the ticker symbol GYRE in mid-2023. Operating primarily in the United States, the company collaborates with academic researchers and industry partners to advance its discovery efforts. Through its innovative focus on membrane biochemistry, Gyre seeks to build a diversified portfolio of first-in-class small-molecule therapies.

View Gyre Therapeutics Profile
Earnings Tools